One can consider the possibility that depending on LC subtype, cells might inhibit the secretion of PON1 protein from the liver cells to the blood, as in our previous study [13], we found an overall reduction of serum PON1 levels in both mouse models and SCLC patients despite dramatic fucosylation levels of the protein, which in this form can persist longer in the blood due to reduced proteolytic degradation. This evidence concerns the gene PON1 and small cell lung carcinoma.